When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
APLS - Achillion Has Multiple Shots On Goal In The Complement Space
Apellis Pharmaceuticals Inc.
Overview/Thesis:
Over this past week, Amgen (AMGN) was rumored to be interested in buying out Alexion (ALXN), the biotech leader in developing treatments for diseases of the complement system, for over $40 billion. Ignored in the hubbub over that rumor was the fact that there simultaneously exists a company trading for less than 1/100th of that proposed buy-out valuation advancing a compound that could ultimately supplant Alexion’s flagship therapies Soliris and its successor Ultomiris. That company is Achillion (ACHN). You have not heard of it because it